Quick Answer
Bone Biologics Corp reported Cash and Equivalents of $6.68 million for fiscal year 2021.
Bone Biologics Corp Cash and Equivalents — Annual History
| Fiscal Year | Cash and Equivalents | YoY Change |
|---|---|---|
| 2021 | $6.68M | +27547.0% |
| 2019 | $24.1K | -97.5% |
| 2018 | $955.4K | +38.4% |
| 2017 | $690.3K | -57.4% |
| 2017 | $1.62M | +107.1% |
| 2017 | $783.0K | -51.4% |
| 2017 | $1.61M | +159.9% |
| 2016 | $620.4K | -9.9% |
| 2016 | $688.2K | -68.6% |
| 2016 | $2.19M | -48.0% |
| 2016 | $4.22M | +278.5% |
| 2015 | $1.12M | -58.1% |
| 2014 | $2.66M | +172942.7% |
| 2013 | $1.5K | +304.7% |
| 2013 | $380.00 | -84.0% |
| 2012 | $2.4K | +374.0% |
| 2012 | $500.00 | — |
| 2011 | $0.00 | — |
Quarterly Cash and Equivalents
| Quarter Ending | Cash and Equivalents | YoY | QoQ |
|---|---|---|---|
| March 31, 2023 | $6.19M | +6.4% | -17.9% |
| December 31, 2022 | $7.54M | +12.9% | +29.6% |
| March 31, 2022 | $5.81M | +8070.6% | -12.9% |
| December 31, 2021 | $6.68M | — | +197747.2% |
| September 30, 2021 | $3.4K | +37.1% | -24.0% |
| June 30, 2021 | $4.4K | — | -93.8% |
| March 31, 2021 | $71.2K | +2826.2% | +2791.7% |
| September 30, 2020 | $2.5K | -98.8% | +1.2% |
- Bone Biologics Corp showed an increase of +27547.0% in Cash and Equivalents compared to the prior fiscal year.
- The most recent figure is from Bone Biologics Corp’s fiscal year 2021 report (Form 10-K), filed with the SEC on March 15, 2022.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: